CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Overview
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
Study Type
- Study Type: Expanded Access
Interventions
- Drug: Rozanolixizumab
- Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
Participating in This Clinical Trial
Inclusion Criteria
- Patient who has taken part in the CIDP04 (NCT04051944) study – Patient who derives continued benefit from treatment – All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records – Patient is not pregnant Exclusion Criteria:
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- UCB Biopharma SRL
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- UCB Cares, Study Director, 001 844 599 2273 (UCB)
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.